Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors

Nikos Vasilakis, Darlene Falvey, Seema S. Gangolli, John Coleman, Jacek Kowalski, Stephen A. Udem, Timothy J. Zamb, Gerald R. Kovacs

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

This report describes a transfection-independent system for packaging alphavirus replicon vectors using modified vaccinia virus Ankara (MVA) vectors to express all of the RNA components necessary for the production of Venezuelan equine encephalitis (VEE) virus replicon particles (VRP). Infection of mammalian cells with these recombinant MVA vectors resulted in robust expression of VEE structural genes, replication of the alphavirus vector and high titers of VRP. In addition, VRP packaging was achieved in a cell type (fetal rhesus lung) that has been approved for the manufacturing of vaccines destined for human use.

Original languageEnglish (US)
Pages (from-to)932-935
Number of pages4
JournalNature Biotechnology
Volume21
Issue number8
DOIs
StatePublished - Aug 1 2003

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Molecular Medicine
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors'. Together they form a unique fingerprint.

  • Cite this

    Vasilakis, N., Falvey, D., Gangolli, S. S., Coleman, J., Kowalski, J., Udem, S. A., Zamb, T. J., & Kovacs, G. R. (2003). Transfection-independent production of alphavirus replicon particles based on poxvirus expression vectors. Nature Biotechnology, 21(8), 932-935. https://doi.org/10.1038/nbt845